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ABSTRACT
Objective: The aim of the present work is the development of new, sensitive, specific, and accurate high-performance liquid chromatographic method 
for the separation and determination of dapagliflozin and its impurities in tablet dosage form.
Methods: The chromatographic separation of drug and its impurities was achieved using Hypersil BDS C18 column (250 mm × 4.6 mm, 5 µ) with 
mobile phase consisted of mobile phase-A (Buffer pH 6.5) and mobile phase-B (acetonitrile:water 90:10) by gradient program at a flow rate of 
1 mL/min with ultraviolet detection at 245 nm.
Results: Dapagliflozin and its impurities A, B, C, D, E, and impurity-F were successfully eluted at the retention time of 16.95, 2.72, 7.82, 10.58, 21.11, 
30.37, and 34.36 min, respectively, with good resolution. The method was validated according to the international conference on harmonization 
guidelines. The validation results showed good precision, accuracy, linearity, specificity, sensitivity, and robustness.
Conclusion: Successful separation and determination of dapagliflozin and its six impurities were achieved by the proposed method. The developed 
method can be applied for the routine analysis of dapagliflozin and its impurities in pharmaceutical formulations.
Keywords: Dapagliflozin, High-performance liquid chromatography method, Impurity.
INTRODUCTION
Dapagliflozin is an antidiabetic drug used for the management of type 2 
diabetes mellitus and belongs to a novel class called sodium glucose 
cotransporter 2 (SGLT2) inhibitor. It is a potent, competitive, reversible, 
highly selective, and orally active inhibitor of SGLT2, the major 
transporter protein responsible for the renal glucose reabsorption. 
By suppressing the SGLT2, dapagliflozin reduces plasma glucose 
concentration by elevating the renal glucose excretion. Hence, it is used 
to treat patients with type 2 diabetes. Dapagliflozin’s mechanism of 
action is different from the mechanisms of other antidiabetic drugs as it 
involves the direct and insulin-dependent elimination of glucose by the 
kidney. It is a synthetic aryl glycoside contains multiple chiral centers, 
but the drug is a single enantiomer and it is chemically described as (2S, 
3R, 4R, 5S, 6R)-2-(4-chloro-3-[4-ethoxybenzy] phenyl)-6-(hydroxyl 
methyl) tetrahydro-2H-pyran-3,4,5-triol [1-3].
Impurities are unwanted chemicals present within the formulation 
and active pharmaceutical ingredient which affects the quality, safety, 
and efficacy of the medicinal products. A significant aspect of ensuring 
the safety of drug products is the qualification of impurities [4]. 
Identification of impurities is done by a variety of chromatographic and 
spectroscopic techniques, either alone or in combination with other 
techniques. The objective of the study was to identify and quantify the 
dapagliflozin and its related impurities A, B, C, D, E, and F [5] (Table 1) in 
the marketed pharmaceutical formulation. Literature survey revealed 
that few analytical methods have been reported for the estimation of 
dapagliflozin alone or in combination with other drugs by ultraviolet 
(UV) spectrometry [6-9], high-performance liquid chromatography 
(HPLC) [10-19], and LC-mass spectrometry [20]. However, there 
is no reported method about the separation and determination of 
dapagliflozin impurities. Hence, an attempt was made to develop 
simple, accurate, precise, and sensitive HPLC method for estimation of 
dapagliflozin in the presence of its above-mentioned impurities.
METHODS
Chemicals and reagents
Dapagliflozin reference standard and impurities were obtained from 
Veeprho laboratories Pvt. Ltd., Pune. Dapagliflozin tablet, Forziga 10 mg, 
was purchased from local market. Analytical grade orthophosphoric 
acid, HPLC grade acetonitrile, methanol, and water were purchased 
from Merck (Mumbai, India).
Instrumentation
The HPLC system used for the method development and validation 
composed of Waters alliance system 2695 separation module with 
autosampler and UV detector. Separation was carried out in a Hypersil 
BDS column C18 column (250 mm × 4.5 mm, 5 µ). The data analysis was 
processed with empower software.
Preparation of mobile phase
Mobile phase-A
Two milliliters of 88% orthophosphoric acid was measured and 
transferred into 2000 ml standard flask, and the volume was made up 
to the mark with HPLC grade water and adjusted the pH of the solution 
to 6.50 using triethylamine.
Mobile phase-B
Acetonitrile and water mixture were prepared in the ratio of 
75:25 % v/v and degassed by sonication.
Preparation of diluent
Mobile phase-B was used as diluent.
Preparation of standard solution
Accurately weighed and transferred about 50 mg of dapagliflozin 
standard into a 50 ml volumetric flask. To this, 30 ml of diluent was 
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added and was sonicated with intermittent shaking to dissolve and 
diluted to the volume with diluents (1000 µg/ml). 5 ml of this solution 
was diluted to 50 ml with diluent (100 µg/ml). Further 5 ml of this 
solution was diluted to 50 ml with diluents (10 µg/ml).
Preparation of sample solution
The commercial dapagliflozin 10 tablets (Forxiga tablet 10 mg) were 
accurately weighed and powdered. From the tablet, powder transferred 
about 50 mg equivalent dapagliflozin sample into a 50 ml volumetric flask. 
To this, 30 ml of diluent was added and sonicated with intermittent shaking 
to dissolve and diluted to the volume with diluent. The solution was filtered 
through a 0.45-µ-membrane filter. The above solution was appropriately 
diluted to get the final concentration of 10 µg/ml sample solution.
Impurities working solution
About 10 mg of all the six impurities were accurately weighed and 
transferred into six different 10 ml volumetric flask, and the volume 
was made up to the mark with diluent (1 mg/ml). 1 ml each of impurity 
stock solution was taken separately in six different 100 ml volumetric 
flask; and the volume was made up to the mark with mobile phase to 
get the concentration of 10 µg/ml for each; and all the solutions were 
studied individually on the HPLC system.
Preparation of impurities mixture
Accurately weighed and transferred about 2 mg each of impurity A, B, 
C, D, E, and F in 10 ml of volumetric flask. To this, 5 ml of diluent was 
added and was sonicated with intermittent shaking to dissolve and 
diluted to volume with diluent (200 µg/ml). The solution was filtered 
through a 0.45-µ-membrane filter.
Preparation of impurities spiked sample solution
Transferred 1ml of the stock solution of the known impurities in 200 ml 
of volumetric flask made up to volume with Dapagliflozin sample 
solution (Dapagliflozin 10 µg/ml and impurities 1.0 µg/ml).
Preparation of resolution solution
Accurately weighed and transferred about 5 mg of impurity-D and 50 mg 
of Dapagliflozin into a 50 ml volumetric flask. To this, 30 ml of diluent 
was added and was sonicated with intermittent shaking to dissolve and 
made up to the volume with diluent. From the above solution, 5 ml was 
diluted to 100 ml with diluents to get the concentration of dapagliflozin, 
50 µg/ml and impurity-D, 5 µg/ml.
Chromatographic conditions
The separation and analysis of all compounds were carried out on 
Hypersil BDS C18 column (250 mm × 4.5 mm, 5 µ) at 50°C, and the 
analytes were monitored with UV detection at 245 nm. A gradient 
mixture of mobile phase-A and mobile phase-B was used at a flow 
rate of 1 ml/min. The LC gradient program was set as follows, 
Time (min)/mobile phase-A: mobile phase-B percentage (%). It was 
programmed as 0–8/75:25, 8–12/55:45, 12–25/55:45, 25–35/40:60, 
35–65/30:70, 65–66/30:70, and 66–75/75:25.
Method validation
The method validation was performed as per the international 
conference on harmonization (ICH) guidelines [21]. The parameters such 
as specificity, linearity and range, precision, accuracy, limit of detection 
(LOD), limit of quantitation (LOQ), and robustness were evaluated.
Specificity
The specificity was demonstrated by injecting blank solution, 
dapagliflozin standard solution, and sample spiked with impurity 
solution, and the chromatograms were checked for interferences [22].
Linearity
The linearity was tested in the concentration range of 0.20–13.00 µg/ml 
for dapagliflozin, 0.26–2.00 µg/ml for impurity-A, 0.21–2.00 µg/ml 
for impurity-B, 0.52–2.00 µg/ml for impurity-C, 0.26–2.00 µg/ml for 
impurity-D, 0.37–2.00 µg/ml for impurity-E, and 0.37–2.00 µg/ml for 
impurity-F.
Precision
The precision was studied by repeatability and intermediate precision 
(ruggedness). The repeatability was checked by injecting the sample 
solution spiked with impurities in six replicates, and the intermediate 
precision was evaluated by different analyst using different columns 
on different days. The percentage relative standard deviation (%RSD) 
of % total impurity was calculated.
Name of compound Chemical name Structure
Dapagliflozin (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzy) phenyl]-6-(hydroxymethyl) 
tetrahydro-2H-pyran-3,4,5-triol
Impurity-A (2S,3R,4R,5S,6R)-2-(4-bromo-3-(4-ethoxybenzyl) phenyl)-6-(hydroxymethyl) 
tetrahydro-2H-pyran-3,4,5-triol




Impurity-E (2S,3R,4R)-2-(4-chloro-3-(4-ethoxybenzyl) phenyl)-5-(1,2-dihydroxyethyl) 
tetrahydrofuran-3,4-diol
Table 1: Chemical name and structure of dapagliflozin and its related impurities[5]
Impurity-F (2R,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl) phenyl)-6-(hydroxymethyl) 
tetrahydro-2H-pyran-3,4,5-triol
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Accuracy
The accuracy of the method was verified by injecting the sample 
solution spiked with impurities at different levels ranging from 70% to 
130% in three replicates, and % mean recovery of each impurity was 
calculated.
Limit of detection and limit of quantitation
LOD is defined as the lowest concentration of an analyte that an 
analytical method differentiates from background levels. The LOQ 
is defined as the lowest concentration that can be measured with 
acceptable accuracy, precision, and variability. The LOD and LOQ were 









Where σ is the standard deviation of the y-intercept and S is the slope 
of the calibration plot.
Robustness
Robustness of the method was verified by deliberately varying the 
instrumental conditions by flow rate (±10%), organic phase ratio 
(±2%), pH of buffer (solution-A) (±0.2), and column oven temperature 
(±5°C). The %RSD of % total impurity was calculated [21-25].
RESULTS AND DISCUSSION
Method development
Analytical detection wavelength of 245 nm was selected for the 
proposed HPLC method based on the UV absorption of dapagliflozin 
and its impurities. Several trials were done to separate dapagliflozin 
from its impurities using various columns and by changing mobile 
phase composition and pH. Finally, the separation of all the impurities 
from the drug peak was achieved with Hypersil BDS column C18 
column (250 mm × 4.5 mm, 5 µ) and with a gradient mixture of the 
mobile phase-A (Buffer pH 6.5) and mobile phase-B (acetonitrile:water 
75:25 % v/v), and the peak shape of the drug and the impurities was 
good. The retention time (RT) of the drug and the impurities were 
identified by analyzing the chromatograms (Fig. 1) of individual 
standard solutions of dapagliflozin and the impurities in five replicates 
under the optimized method conditions.
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The chromatographic system performance was checked by injecting 
the resolution solution prepared with dapagliflozin standard and the 
closely eluted impurity-D, and the chromatogram was recorded (Fig. 2). 
The resolution was found to be 9.80. From the chromatograms of 
resolution, and individual standard solutions of dapagliflozin, and the 
impurities, the system suitability parameters such as the number of 
theoretical plates, tailing factor, and the resolution were calculated. The 
results are listed in Table 2. The chromatographic system is considered 
suitable when it meets the following criteria. The resolution between 
the peaks must be >2, the number of theoretical plates should be more 
than 2000, and tailing factor must be lower than 2.
Method validation
Specificity
The specificity of the method was tested by comparing the 
chromatograms of blank (Fig. 3), dapagliflozin standard solution 
(Fig. 4), and sample spiked with impurity solution (Fig. 5). No 
interference peaks were observed at the RT of dapagliflozin due to the 
blank, impurities, and placebo.
Linearity
The linearity graph was plotted by taking the concentration in the 
x-axis and peak area in y-axis over the calibration ranges tested 
for dapagliflozin and impurities. The data were subjected to linear 
regression analysis, and the regression statistics such as concentration 
range, slope, y-intercept, and correlation coefficient are shown in 
Table 3.
Precision
Precision of the method by repeatability and intermediate precision was 
assessed by injecting sample solution spiked with impurities six times, 
and the results were expressed in terms of %RSD of the percentage of 
total impurities. The results are presented in Table 4.
Accuracy
The accuracy of the proposed method was determined by analyzing 
the dapagliflozin sample solution spiked with impurities at three 
concentration levels of 70%, 100%, and 130% of each impurity in 
triplicate. The mean percentage recovery was calculated and reported 
in Table 5.
Fig 3: Chromatogram of the blank solution
Fig 4: Chromatogram of dapagliflozin standard solution
Fig 5: Chromatogram of sample solution spiked with 
impurities
Fig 2: Chromatogram of resolution for dapagliflozin and 
impurity-D
Table 2: System suitability parameters
System Suitability parameter Imp-A Imp-B Imp-C Dapagliflozin Imp-D Imp-E Imp-F
Retention time 2.72 7.82 10.58 16.95 21.11 30.37 34.36
Theoretical plates 6168 43,350 64,182 18,298 64,685 82,991 87,950
Symmetry factor 1.12 1.03 1.11 0.64 1.11 1.05 1.04
Peak area 128,579 119,169.6 66,577.8 7,906,417 254,283.6 143,306 73,306.6
Percentage RSD of peak area 0.21 0.15 0.13 0.026 0.12 0.21 0.11
Resolution 34.68 17.27 18.75 9.80 24.15 8.81
Imp: Impurity, RSD: Relative standard deviation
Table 3: Linearity evaluation data for dapagliflozin and impurities
Compound name Linearity range (µg/ml) Slope Intercept Correlation coefficient
Impurity-A 0.26–2.00 11978 9.2664 0.9981
Impurity-B 0.21–2.00 15070 82.95 0.9996
Impurity-C 0.52–2.00 6497.5 140.47 0.9979
Dapagliflozin 0.20–13.00 8897.7 490.18 0.9999
Impurity-D 0.26–2.00 25152 25.71 0.9988
Impurity-E 0.37–2.00 15795 980.3 0.9952
Impurity-F 0.37–2.00 8742.6 264.97 0.999
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Limit of detection and limit of quantitation
LOD and LOQ were predicted from the linearity curve using the slope 
and standard deviation of y-intercepts of regression lines, as per the 
ICH guideline. The predicted LOD and LOQ values were verified by 
checking the precision of six replicate injections at that concentration 
for impurity-A, impurity-B, impurity-C, Dapagliflozin, impurity-D, 
impurity-E, and impurity-F, and the results are shown in Table 6.
Robustness
To test the robustness small but deliberate changes were made in the 
method conditions, the samples were analyzed in triplicate and the 
%RSD of percentage of total impurities were calculated for each altered 
condition. In the varied method conditions, all the analytes are well 
resolved, and the elution order of analytes was unchanged. The results 
were summarized in Table 7.
DISCUSSION
Sample number Method precision (total impurities % w/w) Intermediate precision (total impurities % w/w)
Analyst-I, column-I and day-I Analyst-II, column-II and day-II
1 0.146 0.146 0.142
2 0.148 0.148 0.142
3 0.145 0.145 0.161
4 0.146 0.146 0.135
5 0.148 0.148 0.159
6 0.146 0.146 0.145
Mean 0.146 0.146 0.147
SD 0.0012 0.0012 0.0104
Percentage RSD 0.82 0.82 7.07
Overall mean 0.147
Overall SD 0.0071
Overall percentage RSD 4.83
RSD: Relative standard deviation, SD: Standard deviation
Compound name LOD (µg/ml) LOQ (µg/ml) Precision at LOD level Precision at LOQ level
Mean peak area*±SD Percentage RSD Mean peak area*±SD Percentage RSD
Impurity-A 0.084 0.253 944±125.81 13.33 3078±212.25 6.90
Impurity-B 0.042 0.127 749±113.12 15.10 2027±198.75 9.81
Impurity-C 0.217 0.434 1286±99.40 7.73 2676±127.59 4.77
Dapagliflozin 0.065 0.196 949±57.54 6.06 2092±153.63 7.34
Impurity-D 0.071 0.216 1688±213.6 12.66 5151±212.38 4.12
Impurity-E 0.114 0.345 1478±271.3 18.36 5027±243.61 4.85
Impurity-F 0.176 0.352 2046±156.9 7.67 3495±140.28 4.01
Overall mean percentage RSD 11.55 5.97
*n=6. LOD: Limit of detection, LOQ: Limit of quantitation, RSD: Relative standard deviation, SD: Standard deviation
Table 5: Results of accuracy study
Recovery level (%) Mean recovery* (%)
Impurity-A Impurity-B Impurity-C Impurity-D Impurity-E Impurity-F
70 103.02 96.08 92.14 96.37 104.27 103.02
100 104.44 101.47 99.99 101.37 98.50 102.22
130 104.42 104.36 98.17 102.25 99.38 102.76
Overall mean 103.96 100.63 96.76 99.99 100.71 102.67
Overall SD 1.940 3.647 4.883 2.788 3.528 1.209
Overall percentage RSD 1.87 3.66 4.96 2.80 3.48 1.18
*n=3. RSD: Relative standard deviation, SD: Standard deviation
Table: 4 Results of the precision study
Table 6: Limit of detection and limit of quantitation data
According to the literature review, there is no HPLC method development 
was reported for simultaneous estimation of dapagliflozin and its 
impurities. In the proposed method under optimized chromatographic 
conditions, the dapagliflozin and its impurities were well separated with 
good peak shape and proper RT. System suitability test results confirm 
that the developed method is  suitable for the analysis  of  impurities in the 
drug  product.  The  results  of  method  validation  parameters  are 
within the acceptance criteria as per the ICH guidelines [21].  The 
specificity  study  meets  the  acceptance  criteria  [21],  as  that  no 
interference  was  observed  from  the  blank  at  the  RT  of  known 
impurities.  It  is  evident  that  from  the  obtained  data  that  all  the 
peaks  were  well  resolved,  and  the  method  is  said  to  be  specific. 
The  result  of  linearity  study  shows  excellent  correlation  existed 
between the peak area and concentration of the drug dapagliflozin and
 impurities,  and  the  correlation  coefficient  of  the  drug  and 
impurities complied with the acceptance limit (not ≥0.95) [22]. 
The obtained precision data represent no significant variation in 
the  measured  response  and  demonstrate  that  the  method  is 
repeatable  and  rugged  with  the  %RSD  value  below  4.83  which  meets 
the  acceptance  limit  (<10%)  [22].  The  mean  %  recovery  of 
recovery  study  was  in  the  range  of  96.76–103.96.  This  range 
complies  with  the  acceptance  criteria  [22]  85%–115%,  thus 
confirming  the  accuracy  of  the  method.  The  mean  %RSD  of 
precision at LOD and LOQ level was below 11.55 (acceptance limit – 
<15%) [22], and the very low LOD and LOQ values when compared to 
the  reported  method  [25]  indicate  the  sensitivity  of  the  developed 
method  for  determination  of  dapagliflozin  impurities.  The 
satisfactory mean %RSD value of robustness study exhibits the 
proposed  method  which  is  robust  enough  to  withstand  the  small 
variations of method conditions.
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CONCLUSION
The quality and safety of the drug product not only depends on the 
adopted manufacturing procedure and toxicological properties of an 
active substance but also depends on the impurities that it contains. 
Hence, a thorough examination of related impurities plays a significant 
role in controlling the quality of a drug product. In the current research 
work, a simple, sensitive, specific, and accurate HPLC method was 
developed for separation and determination of dapagliflozin in the 
presence of its related impurities. The developed method was validated 
as per the ICH guidelines and it was found to be precise, linear, rugged, 
and robust. Hence, the present method can be adapted to separate, 
identify, and quantify the related impurities of dapagliflozin in its 
pharmaceutical formulations. Application of this method in quality 
control shall improve the safe use of medicinal products which contain 
dapagliflozin as an active substance.
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